Peregrine and Stason Agree on Innovative Tumor Necrosis Therapy Technologies

Peregrine Pharmaceuticals … and Stason Pharmaceuticals, a privately-held U.S.-based pharmaceutical company commercializing products globally since 1994, Monday announced agreements granting Stason certain exclusive development and commercialization rights to Peregrine’s tumor necrosis therapy technologies.
MarketWatch